Status:
COMPLETED
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Lead Sponsor:
Novartis Vaccines
Conditions:
Influenza
Fever
Eligibility:
All Genders
4-17 years
Phase:
PHASE3
Brief Summary
Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
Eligibility Criteria
Inclusion
- \- Healthy subjects 4-17 years of age
Exclusion
- Subjects who are not healthy,
- Subjects who are pregnant or breast feeding,
- Subjects with a history of severe allergic reaction or allergic to any of the vaccine components.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
2055 Patients enrolled
Trial Details
Trial ID
NCT01857206
Start Date
May 1 2013
End Date
June 1 2014
Last Update
December 5 2014
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
320, Novartis Investigational Site
Mobile, Alabama, United States, 36608
2
312, Novartis Investigational Site
Ponte Vedra, Florida, United States, 32081
3
313, Novartis Investigational Site
Augusta, Kansas, United States, 67010
4
305, Novartis Investigational Site
Newton, Kansas, United States, 67114